Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National PopulationBased Cohort Study

CONCLUSION: The findings of this study indicate that nilotinib treatment is associated with increased risks of diabetes and hyperlipidemia, with hyperlipidemia being the most significant risk for CVDs. Therefore, we recommend that CML patients receiving nilotinib should undergo screening for diabetes and hyperlipidemia prior to initiating TKI treatment. Additionally, regular monitoring of lipid profiles during TKI therapy and implementing effective management strategies to control hyperlipidemia are crucial.PMID:37561957 | DOI:10.1093/oncolo/oyad225

Source: The Oncologist - August 10, 2023 Category: Cancer & Oncology Authors: Cih-En Huang Kuan-Der Lee Jung-Jung Chang Huey-En Tzeng Shih-Hao Huang Lennex Hsueh-Lin Yu Min-Chi Chen Source Type: research